Fresh, sourced stories worth posting about for physicians — updated every few hours, with the receipts attached. Not generated guesses.
Your desk is ready
Free to start · no card required · your pick is waiting on the other side.
Niche's weekly rollup — one email, no spam.
The stories refresh every few hours from live news and primary sources. Each carries the publisher and the date it was published — so you can see exactly how current it is.
Real reporting and primary filings — every story links its sources. Nothing here is a generated guess; the angle is identified and the receipts are attached.
Yes. These are starting points for your own posts. Draft one and Niche writes it in your voice, platform-native, ready to publish.
CDC and FDA-linked alerts describe a large cyclosporiasis surge tied to iceberg lettuce, a multistate Cyclospora investigation, a Salmonella recall involving moringa leaf powder, and ongoing travel guidance for Ebola and chikungunya exposure. A separate respiratory illness surveillance update adds context that seasonal acute respiratory burden remains low even as other outbreaks circulate.
Draft a post from this →A broad set of NIH awards spans neurology, nephrology, hematology-oncology, infectious disease, reproductive health, and oral oncology, highlighting continued federal support for academic medical centers and physician-led research programs. These grants provide context for medical education, trial infrastructure, and translational work that feeds future specialty care.
Draft a post from this →Signals point to a cluster of medication-safety and regulatory changes affecting how physicians prescribe and counsel patients, including the removal of long-standing hormone therapy warnings, an FDA safety update on JAK inhibitors, and an Amgen regulatory submission for TAVNEOS. A peptides advisory discussion also reflects ongoing FDA scrutiny of emerging therapies that may reach clinical practice.
Draft a post from this →Signals around prescription drug costs and the broader rate environment suggest continued pressure on practice economics and patient affordability. With Treasury yields and the yield spread still elevated but less inverted, the macro backdrop remains relevant to physician practices facing borrowing costs, valuation changes, and payer affordability constraints.
Draft a post from this →The Paragard IUD settlement update and Depo-Provera brain-tumor litigation both keep physician counseling, informed consent, and product-liability risk in focus for OB-GYN and primary care practices. The hormone therapy warning rollback also sits nearby as part of a broader women’s health conversation about safety communication and prescribing.
Draft a post from this →